Stock Analysis
Haisco Pharmaceutical Group Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Haisco Pharmaceutical Group (SZSE:002653) Second Quarter 2024 Results
Key Financial Results
- Revenue: CN¥934.5m (up 25% from 2Q 2023).
- Net income: CN¥72.8m (up 57% from 2Q 2023).
- Profit margin: 7.8% (up from 6.2% in 2Q 2023). The increase in margin was driven by higher revenue.
- EPS: CN¥0.068 (up from CN¥0.037 in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Haisco Pharmaceutical Group EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 2.0%. Earnings per share (EPS) exceeded analyst estimates by 17%.
Looking ahead, revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China.
Performance of the Chinese Pharmaceuticals industry.
The company's shares are up 4.3% from a week ago.
Balance Sheet Analysis
While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We've done some analysis and you can see our take on Haisco Pharmaceutical Group's balance sheet.
Valuation is complex, but we're here to simplify it.
Discover if Haisco Pharmaceutical Group might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SZSE:002653
Haisco Pharmaceutical Group
Research, develops, manufactures, and sells pharmaceuticals in China.